It has been suggested, based on rodent studies, that levodopa (L-dopa) induced dyskinesia is associated with a disrupted blood-brain barrier (BBB). We have investigated BBB integrity with in vivo neuroimaging techniques in six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned primates exhibiting Ldopa-induced dyskinesia. Magnetic resonance imaging (MRI) performed before and after injection of Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) revealed an intact BBB in the basal ganglia showing that L-dopa-induced dyskinesia is not associated with a disrupted BBB in this model.
Introduction
Levodopa (L-dopa) is currently the primary treatment of motor symptoms in Parkinson's disease (PD). However, a major limitation of chronic L-dopa treatment is the development of dyskinesias after years of treatment (Fahn, 2003; Olanow et al., 2004) . The pathophysiological mechanisms of L-dopa-induced dyskinesia are poorly understood, though non-physiological release of synaptic dopamine is likely to play a major role in its development (Obeso et al., 2000; Olanow et al., 2004; Olanow and Obeso, 2000) . Recently, it has been suggested, based on studies in rodents, that L-dopa-induced dyskinesia may be associated with a disrupted blood-brain barrier (BBB) (Westin et al., 2006) and that this may in turn contribute to its pathophysiology, by further exacerbating dyskinesia (Westin et al., 2006) .
The purpose of the present study was to investigate the integrity of the BBB using in vivo neuroimaging techniques in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned parkinsonian primates exhibiting L-dopa-induced dyskinesias.
Methods

Induction of parkinsonian and dyskinetic symptoms
Six adult male macaque monkeys (Macaca fascicularis), aged 6-8 years and weighing 6-7 kg, were included in this study. Animals were housed in individual home cages at the New England Primate Research Center (NEPRC). All studies were approved by the Harvard Medical School Institutional Animal Care and Use Committee (IACUC). Parkinsonism was induced by weekly intravenous administration of low doses of MPTP (Sigma-Aldrich ® ) diluted in normal saline. Doses were given initially at 0.30 mg/kg to all animals but in some instances subsequently reduced to 0.15 mg/kg, due to symptom severity and individual sensitivity. Parkinsonian motor symptoms were rated weekly during and after MPTP administration on a Parkinson's Rating Scale (PRS) as developed for macaques (Imbert et al., 2000) and modified from the motor subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) (Fahn, 2003) , ranging from 0 to 24, with 24 being most severe. Stable PRS scores were obtained off L-dopa at least 3 months after the last MPTP dose and were considered stable if standard deviation did not change more than ±2 over 6 weeks ( 
